A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Global Incidence of Pertussis After the COVID-19 Pandemic




TekijätGorringe, Andrew; Cavell, Breeze; Beard, Frank; Tsukada, Keiko; Otsuka, Nao; Fu, Pan; Moosa, Fahima; Fabianova, Katerina; Rodrigues, Carla; Bouchez, Valerie; Toubiana, Julie; Brisse, Sylvain; Dalby, Tine; He, Qiushui; Campbell, Helen; Hozbor, Daniela; Hariri, Susan; Pawloski, Lucia; Scanlon, Karen; Edwards, Kathryn

KustantajaJAMA Network

Julkaisuvuosi2025

Lehti: JAMA Network Open

Artikkelin numeroe2545963

Vuosikerta8

Numero12

eISSN2574-3805

DOIhttps://doi.org/10.1001/jamanetworkopen.2025.45963

Julkaisun avoimuus kirjaamishetkelläAvoimesti saatavilla

Julkaisukanavan avoimuus Kokonaan avoin julkaisukanava

Verkko-osoitehttps://doi.org/10.1001/jamanetworkopen.2025.45963

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/505793239


Tiivistelmä

Importance  Pertussis, or whooping cough, is caused by the Bordetella pertussis bacterium. It induces prolonged cough in all age groups and is a severe, life-threatening disease in young infants.

Observations  In an online workshop organized by the International Bordetella Society on November 12, 2024, most participating countries reported very low pertussis incidence during and immediately following the COVID-19 pandemic. Since that time, many countries have seen large outbreaks of pertussis, particularly in adolescents. Before the pandemic, several countries, especially those using acellular pertussis vaccine in infants, reported circulating B pertussis isolates that lacked the acellular vaccine antigen pertactin. However, most recent isolates have been found to express this antigen. A rise in macrolide-resistant B pertussis isolates was also reported by several countries.

Conclusions and Relevance  The potential for large outbreaks of pertussis highlights the importance of maintaining or increasing vaccine coverage in pregnancy and in infants and children. The data presented herein suggest a need for new pertussis vaccines that protect against both disease and infection and that reduce transmission.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Julkaisussa olevat rahoitustiedot
The sponsor of this work was the International Bordetella Society, and the work was led by several members of the society. No additional funding was provided to the presenters for this work.


Last updated on